ERBB2 and breast cancer: Other studies found that PIK3CA mutations are more frequent in HER2+ and luminal breast cancer; it might be that we defined a subgroup of TNBCs where PIK3CA mutations are also frequent, i.e., the non-BRCA subgroups.